Cydan is an orphan drug accelerator that identifies and de-risks compounds with therapeutic and commercial potential. Their rigorous process generates data to support a development path and new company formation. Cydan’s experienced and globally networked team brings strong relationships with academia and patient advocacy, deep expertise in drug development, and a track record of successful product commercialization.